Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

PHASE4RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

November 1, 2025

Conditions
AdrenoleukodystrophyRestless Legs Syndrome
Interventions
DRUG

Pramipexole

Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.

DRUG

Placebo

Matching placebo

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital, Boston

Unknown

RECRUITING

University Medical Center of Amsterdam, Amsterdam

All Listed Sponsors
collaborator

European Leukodystrophy Association

OTHER

lead

Massachusetts General Hospital

OTHER

NCT05003648 - Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy | Biotech Hunter | Biotech Hunter